Back

COVID-19 vaccine-induced myocarditis vs. Immune checkpoint inhibitor-induced myocarditis - Same but different?

29 August 2022 (10:15 - 11:00)
Organised by:
Congress Presentation Part of: COVID-19 and cardiovascular disease in special populations Cardio-Oncology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

5 More presentations in this session

Presentation thumbnail
Impaired endothelial glycocalyx, vascular dysfunction and myocardial deformation four months after COVID-19 infection are partially improved at twelve months.
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Predictors and clinical consequences of heart damage in CMR in patients after COVID-19
Doctor M. Chudzik (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Parameters of coagulation and platelet hyperreactivity reflect an increased mortality in patients with moderate to severe COVID-19
Mr K. Jakobs (Berlin, DE)
Abstract Slides
Presentation thumbnail
Galectin-3 as a possible marker for increased thrombogenicity in COVID-19
Ms M. Puccini (Berlin, DE)
Abstract Slides
Presentation thumbnail
Pragmatic observations from a post-Covid-19 cardiac evaluation register: prevalence of cardiological alterations from a basic diagnostic sequence and contribution of the clinical hystory.
Doctor G. Ruiz (Buenos Aires, AR)
Abstract Slides

Access the full session

Session thumbnail
COVID-19 and cardiovascular disease in special populations

The Event

Event poster

ESC Congress 2022

29 August 2022 10:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources